Wednesday, June 29, 2016

BRIEF-Lipocine gets complete response letter for LPCN 1021 from FDA

* Lipocine receives complete response letter (crl) for LPCN

1021 From U.S. Food And Drug Administration

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)